Psoriatic Arthritis, sequential use of biological agendts in the management of - Pan Mersey APC Skip to main content Help with accessibility Skip to main navigation

Psoriatic Arthritis, sequential use of biological agendts in the management of

Last Updated: 28 June 2017

Body System: Musculoskeletal system

Red

The Pan Mersey Area Prescribing Committee recommends the sequential use of biological agents, adalimumab, certolizumab, etanercept, golimumab, infliximab, secukinumab▼ and ustekinumab in the management of psoriatic arthritis (PsA) in accordance with the recommendations below, and the accompanying flowchart.